FDA’s first clearance of AI for autonomous detection of diabetic retinopathy
A system designed by a University of Iowa ophthalmologist that uses artificial intelligence (AI) to detect diabetic retinopathy without a person interpreting the results earned Food and Drug Administration (FDA) authorization in April, following a clinical trial in primary care offices.
Results of that study were published Aug. 28 online in Nature Digital Medicine, offering the first look at data that led to FDA clearance for IDx-DR, the first medical device that uses AI for the autonomous detection of diabetic retinopathy.
The clinical trial, which also was the first study to prospectively assess the safety of an autonomous AI system in patient care, compared the performance of IDx-DR to the gold standard diagnostic for diabetic retinopathy, which is the leading cause of vision loss in adults and one of the most severe complications for the 30.3 million Americans living with diabetes.
IDx-DR exceeded all pre-specified superiority endpoints in sensitivity, the ability to correctly identify a patient with disease; specificity, the ability to correctly classify a person as disease-free; and imageability, or the capability to produce quality images of the retina and determine the severity of the disease.
“The AI system’s primary role is to identify those people with diabetes who are likely to have diabetic retinopathy that requires further evaluation by an eye-care provider. The study results demonstrate the safety of autonomous AI systems to bring specialty-level diagnostics to a primary care setting, with the potential to increase access and lower cost,” says Michael Abràmoff, MD, PhD, the Robert C. Watzke Professor of Ophthalmology and Visual Sciences with UI Health Care and principal investigator on the study. He is founder and president of IDx, the company that created the IDx-DR system and funded the study.
Early detection may prevent vision loss
More than 24,000 people in the United States lose their sight to diabetic retinopathy each year. Early detection and treatment can reduce the risk of blindness by 95 percent, but less than 50 percent of patients with diabetes schedule regular exams with an eye-care specialist.
In the study, 900 adult patients with diabetes—but no history of diabetic retinopathy—were examined at 10 primary care sites across the country. Retinal images of the patients were obtained using a robotic camera, with an AI assisting the operator in getting good quality images.
Once the four images were complete, the diagnostic AI then made a clinical diagnosis in 20 seconds. The diagnostic AI detects disease just as expert clinicians do, by having detectors for the lesions characteristic for diabetic retinopathy, including microaneurysms, hemorrhages, and lipoprotein exudates.
Camera operators in the study were existing staff of the primary care clinics, and not physicians or trained photographers.
“This was much more than just a study testing an algorithm on an image. We wanted to test it in the places where it will be used, by the people who will use it, and we compared it to the highest standard in the world,” says Abràmoff, who also holds faculty appointments in the UI College of Engineering.
AI measured against gold standard
Study participants also had retinal images taken at each of the primary care clinics using specialized widefield and 3D imaging equipment without AI and operated by experienced retinal photographers certified by the Wisconsin Fundus Photograph Reading Center (FPRC)—the gold standard in grading the severity of diabetic retinopathy.
Complete diagnostic data accomplished by both the AI system and FPRC readers was available for 819 of the original 900 study participants. FPRC readers identified 198 participants with more than mild diabetic retinopathy who should be further examined by a specialist; the AI was able to correctly identify 173 of the 198 participants with disease, resulting in a sensitivity of 87 percent. Among the 621 disease-free participants identified by FPRC readers, AI identified 556 participants, for a specificity of 90 percent. The AI had a 96 percent imageability rate: of the 852 participants who had an FPRC diagnosis, 819 had an AI system diagnostic output.
The Latest on: IDx-DR
via Google News
The Latest on: IDx-DR
- AI diagnostic system accuracy holds up to industry standards on September 10, 2018 at 1:24 pm
The artificial intelligence diagnostic system, IDx-DR, detects more than mild diabetic retinopathy and diabetic macular edema with significantly relevant sensitivity and specificity and has potential ... […]
- Dr. Eric Topol turns critical eye on landmark FDA-approved AI device on September 5, 2018 at 11:51 am
The software, IDx-DR, applies an artificial intelligence algorithm to images of a patient's eye to detect diabetic retinopathy, a diabetes-related eye disease. Since IDx-DR offers its decision without ... […]
- AI Speeds Diabetic Retinopathy Diagnosis Without Specialist on August 30, 2018 at 7:15 am
Results from the prospective study evaluating the platform, called IDx-DR (IDx LLC), were convincing enough for the US Food and Drug Administration (FDA) to fast-track its approval in April. It was "t... […]
- Pivotal trial results behind the FDA's first ever clearance of an autonomous AI diagnostic system published in "Nature Digital Medicine" on August 28, 2018 at 7:24 am
CORALVILLE, Iowa, Aug. 28, 2018 /PRNewswire/ -- Pivotal trial results assessing the safety and efficacy of IDx-DR, an autonomous AI diagnostic system that detects diabetic retinopathy, were published ... […]
- AI system can detect diabetic retinopathy on August 28, 2018 at 6:45 am
The trial compared the performance of IDx-DR to the gold standard diagnostic for diabetic retinopathy, which is the leading cause of vision loss in adults. The study, which was published Tuesday in th... […]
- Q&A: New AI system that tests for diabetic eye disease on July 6, 2018 at 12:13 pm
As for technology, digital imaging has fueled AI development for innovations like IDx-DR, creating new solutions to the problems we have in healthcare. Arguably advances in health technology are under... […]
- FDA greenlights tool for automated detection of diabetic retinopathy in primary care on April 13, 2018 at 9:32 am
IDx-DR is designed to automate the detection of diabetic retinopathy, a complication of diabetes, and is intended to be used by primary care physicians The size of the problem is massive. Many of the ... […]
- The FDA just opened the door to let AI make medical decisions on its own on April 13, 2018 at 4:18 am
The software is called IDx-DR, made by diagnostic AI startup IDx, and specifically analyzes images of the retina to detect whether a person with diabetes has a complication from the disease called dia... […]
- US FDA grants marketing approval for AI-based device, IDx-DR to detect certain diabetes-related eye problems on April 13, 2018 at 3:51 am
The US Food and Drug Administration (FDA) permitted marketing of the first medical device to use artificial intelligence (AI) to detect greater than a mild level of the eye disease diabetic retinopath... […]
via Bing News